Skip to content

Alnylam 制药

US · ALNY #627 按市值排名 上市于 1970
231.83 -2.20 -0.94%
实时 - 追踪5344个代码 - 心跳于147秒前 · 2026-10-16 18:18

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量减少了2家。
  • 机构持股总比例下降了0.6个百分点。

机构持股

机构持股比例
101.48% -0.63pp
机构数量
1,002 -2
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund87.48%
Hedge Fund5.72%
Public Company2.90%
Sovereign Wealth Fund1.89%
Government Pension Fund1.53%
Private Company0.79%
VC/PE Fund0.77%
Individual/Insider0.39%
Insurance Company0.21%

主要股东 截至 2026-06-30

Capital Research 15.71% · 21.01M 股
FMR 10.66% · 14.27M 股
BlackRock 8.15% · 10.91M 股
Vanguard Capital Management, LLC 5.15% · 6.89M 股
T. Rowe Price Group, Inc. 5.08% · 6.79M 股
Vanguard Portfolio Management, LLC 4.89% · 6.54M 股
Invesco Capital Management LLC 2.73% · 3.65M 股
State Street Global Advisors 2.66% · 3.56M 股
Geode Capital Management, LLC 1.97% · 2.64M 股
Baillie Gifford 1.82% · 2.44M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 30次买入 · 18次卖出

姓名职务持股比例
Phillip Sharp Co-Founder, Member of the Scientific Advisory Board & Independent Director 0.20%
Yvonne Greenstreet Chief Executive Officer 0.05%
Jeffrey Poulton Chief Financial Officer 0.03%
David E. Pyott Independent Director 0.02%
Amy W. Schulman Chair of the Board & Lead Independent Director 0.02%
Michael Bonney Non-Independent Director 0.01%
Tolga Tanguler Executive Vice President 0.01%
Pushkal Garg Chief Medical Officer and Executive VP of Development & Medical Affairs 0.01%
Kevin Fitzgerald Senior VP, Head of Research & Chief Scientific Officer 0.01%
Bryan Supran Chief Legal Officer 0.01%
Melissa McLaughlin Chief Human Resources Officer 0.01%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-10-01 Bryan Supran Chief Legal Officer Intent to Sell (Form 144) -1,758 $226.88
2026-09-18 Yvonne Greenstreet Chief Executive Officer Other Acquisition +107 --
2026-05-31 David E. Pyott Independent Director Derivative Exercise and Sale -3,830 $297.71–302.65
2026-05-31 Benjamin Cravatt Director Other Derivative Acquisition +4,393 $295.63
2026-05-19 Peter Kellogg Independent Director Other Acquisition +671 --
2026-05-19 Peter Kellogg Independent Director Other Derivative Acquisition +1,441 $298.48
2026-05-19 David E. Pyott Independent Director Other Acquisition +671 --
2026-05-19 David E. Pyott Independent Director Other Derivative Acquisition +1,441 $298.48
2026-05-19 Charles Sigal Independent Director Other Acquisition +671 --
2026-05-19 Charles Sigal Independent Director Other Derivative Acquisition +1,441 $298.48
2026-05-19 Margaret Hamburg Independent Director Other Acquisition +671 --
2026-05-19 Margaret Hamburg Independent Director Other Derivative Acquisition +1,441 $298.48
2026-05-19 Amy W. Schulman Chair of the Board & Lead Independent Director Other Acquisition +838 --
2026-05-19 Amy W. Schulman Chair of the Board & Lead Independent Director Other Derivative Acquisition +1,802 $298.48
2026-05-19 Dennis Ausiello Member of the Scientific Advisory Board & Independent Director Other Acquisition +671 --
2026-05-19 Dennis Ausiello Member of the Scientific Advisory Board & Independent Director Other Derivative Acquisition +1,441 $298.48
2026-05-19 Colleen Reitan Independent Director Other Acquisition +671 --
2026-05-19 Colleen Reitan Independent Director Other Derivative Acquisition +1,441 $298.48
2026-05-19 Olivier Brandicourt Independent Director Other Acquisition +671 --
2026-05-19 Olivier Brandicourt Independent Director Other Derivative Acquisition +1,441 $298.48

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 18:18:36 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

Alnylam 制药 讨论区 0 条评论

发表评论